We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+13.43%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$175M
AUM Growth
-$45.7M
Cap. Flow
-$47M
Cap. Flow %
-26.94%
Top 10 Hldgs %
95.55%
Holding
25
New
4
Increased
3
Reduced
2
Closed
8

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$5.01M
2
CNTX icon
Context Therapeutics
CNTX
+$2.22M
3
TARA icon
Protara Therapeutics
TARA
+$1.4M
4
RZLT icon
Rezolute
RZLT
+$1.37M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$718K

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$10.1M
2
INSP icon
Inspire Medical Systems
INSP
+$3.87M
3
AQST icon
Aquestive Therapeutics
AQST
+$2.56M
4
OTLK icon
Outlook Therapeutics
OTLK
+$2.03M
5
GERN icon
Geron
GERN
+$1.65M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALIM
1
DELISTED
Alimera Sciences
ALIM
$75.7M 43.35%
13,608,533
– –
JSPR icon
2
Jasper Therapeutics
JSPR
$23.6M
$32.5M 18.65%
1,471,904
– –
HRTX icon
3
Heron Therapeutics
HRTX
$92.9M
$24.5M 14.01%
6,986,744
– –
PRAX icon
4
Praxis Precision Medicines
PRAX
$10.1B
$14.5M 8.31%
350,666
– –
TRML
5
DELISTED
Tourmaline Bio
TRML
$4.1M 2.35%
319,080
– –
TELA icon
6
TELA Bio
TELA
$38.9M
$3.51M 2.01%
746,087
– –
RZLT icon
7
Rezolute
RZLT
$452M
$3.44M 1.97%
800,000
+400,000
+100% +$1.37M
SKYE icon
8
Skye Bioscience
SKYE
$18.3M
$3.38M 1.94%
+422,142
New +$5.01M
OPTN
9
DELISTED
OptiNose
OPTN
$2.59M 1.49%
166,189
-33,890
-17% -$568K
CNTX icon
10
Context Therapeutics
CNTX
$44.5M
$2.59M 1.48%
+1,290,323
New +$2.22M
NSPR icon
11
InspireMD
NSPR
$34.7M
$2.26M 1.29%
904,029
– –
OTLK icon
12
Outlook Therapeutics
OTLK
$191M
$1.82M 1.04%
247,084
-252,916
-51% -$2.03M
ELEV
13
DELISTED
Elevation Oncology
ELEV
$1.61M 0.92%
597,299
+100,000
+20% +$377K
TARA icon
14
Protara Therapeutics
TARA
$232M
$998K 0.57%
+480,000
New +$1.4M
KPRX icon
15
Kiora Pharmaceuticals
KPRX
$11.7M
$513K 0.29%
122,223
+1
+0% +$5
XFOR icon
16
X4 Pharmaceuticals
XFOR
$460M
$382K 0.22%
+21,967
New +$718K
ASLN
17
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$188K 0.11%
78,125
– –
ADMA icon
18
ADMA Biologics
ADMA
$2.22B
– –
-1,528,601
Closed -$10.1M
AQST icon
19
Aquestive Therapeutics
AQST
$494M
– –
-600,000
Closed -$2.56M
GERN icon
20
Geron
GERN
$949M
– –
-500,000
Closed -$1.65M
INSP icon
21
Inspire Medical Systems
INSP
$1.74B
– –
-18,000
Closed -$3.87M
IWM icon
22
PUT
iShares Russell 2000 ETF
IWM
$81.9B
– –
-100,000
Closed -$21M
MIST icon
23
Milestone Pharmaceuticals
MIST
$152M
– –
-650,000
Closed -$1.16M
NVNO
24
enVVeno Medical
NVNO
$7.08M
– –
-4,921
Closed -$937K
XBI icon
25
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-150,000
Closed -$14.2M

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
RFS
Richardson Financial Services Medway, Massachusetts $160M AUM 16.71% 1-Year Est. Return
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
CF
CBM Financial Austin, Texas $160M AUM

Velan Capital Investment Management's Q2 2024 Portfolio in Review

As of Q2 2024, Velan Capital Investment Management held 25 positions worth $175M, down 21% from $220M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Velan Capital Investment Management withdrew a net $47M in Q2 2024, closing 8 positions and reducing 2 holdings. Its most notable exit was ADMA Biologics, an estimated $10.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier.

Against the trend, Velan Capital Investment Management opened a new position in Skye Bioscience worth $3.38M.

  • Velan Capital Investment Management's largest Q2 2024 buy was Skye Bioscience: 422,142 shares worth $3.38M.
  • Velan Capital Investment Management added most to Rezolute in Q2 2024, an estimated $1.37M increase.
  • Velan Capital Investment Management's biggest Q2 2024 reduction was Outlook Therapeutics, cutting an estimated $2.03M.
  • Velan Capital Investment Management fully exited ADMA Biologics in Q2 2024, selling an estimated $10.1M.
  • Velan Capital Investment Management's ten largest holdings make up 96% of its $175M portfolio in Q2 2024.
  • Velan Capital Investment Management opened 4 new positions and closed 8 in Q2 2024.
  • Velan Capital Investment Management's portfolio value fell 21% quarter-over-quarter to $175M.

Based on Velan Capital Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.